ArticleFrontiers in microbiology2024
Cinnamaldehyde nanoemulsion decorated with rhamnolipid for inhibition of methicillin-resistant
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virulence arresting drug discovery by strategies targeting bacterial virulence: Mainly focusing on quorum-sensing interference and biofilm inhibition.Journal of pharmaceutical analysis · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The formulation of cinnamaldehyde nanoemulsion (Cin-NE) combined with rhamnolipid (RHL) was developed by self-assembly, and the efficacies of this formulation in inhibiting Results: The particle size of the selected Cin-NE formulation was 13.66 ± 0.08 nm, and the Cin-RHL-NE formulation was 20.45 ± 0.25 nm. The selected Cin-RHL-NE formulation was stable at 4, 25, and 37°C. Furthermore, the Minimum Inhibitory Concentration (MIC) value of Cin-RHL-NE against MRSA was two-fold lower than drug solution. Confocal laser scanning microscopy (CLSM) revealed the superior efficacy of Cin-RHL-NE in eradicating MRSA biofilms while maintaining the Cin's inherent functional properties. The efficacy of Cin-RHL-NE in the mouse skin wound healing model was superior to other formulation. Conclusion: These findings highlight the potential of the formulation Cin-RHL-NE for eradicating biofilms, and effective in treating notoriously persistent bacterial infections. The Cin-RHL-NE can used as a dosage form of Cin application to bacterial biofilm associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.